Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition
- PMID: 20593491
- DOI: 10.1002/path.2721
Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition
Abstract
Angiotensin II (Ang II) is a key mediator of chronic kidney disease, in which epithelial-mesenchymal transition (EMT) is a critical process mediated by the TGFbeta/Smad signalling pathway. The present study examined the specific role of Smads in Ang II-induced EMT in vitro and in vivo. We found that Ang II signalled through the receptor of AT1, not AT2, to activate Smad2/3 and induce EMT in a normal rat tubular epithelial cell line (NRK52E). Activation of Smads by Ang II was attributed to degradation of an inhibitory Smad7, which was mediated by the AT1-Smurf2-dependent ubiquitin degradation mechanism because blockade of AT1 receptor or knockdown of Smurf2 inhibited Smad7 loss, thereby reducing Smad2/3 activation and EMT in response to Ang II. In contrast, over-expression of Smad7 inhibited Ang II-induced Smad2/3 activation and EMT in NRK52E cells and in a rat model of remnant kidney disease. Moreover, knockdown of Smad3, not Smad2, attenuated Ang II-induced EMT. In conclusion, Ang II activates Smad signalling to induce EMT, which is mediated by a loss of Smad7 through the AT1-Smurf2-dependent ubiquitin degradation pathway. Smad3, but not Smad2, may be a mediator of EMT, while Smad7 may play a protective role in EMT in response to Ang II.
Similar articles
-
Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3.Hypertension. 2009 Oct;54(4):877-84. doi: 10.1161/HYPERTENSIONAHA.109.136531. Epub 2009 Aug 10. Hypertension. 2009. PMID: 19667256
-
Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation.Phytomedicine. 2018 Mar 15;42:207-218. doi: 10.1016/j.phymed.2018.03.034. Epub 2018 Mar 19. Phytomedicine. 2018. PMID: 29655688
-
Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFβ signalling and EMT.Oncogene. 2011 May 26;30(21):2451-62. doi: 10.1038/onc.2010.617. Epub 2011 Jan 24. Oncogene. 2011. PMID: 21258410 Free PMC article.
-
Transforming growth factor-β/Smad signalling in diabetic nephropathy.Clin Exp Pharmacol Physiol. 2012 Aug;39(8):731-8. doi: 10.1111/j.1440-1681.2011.05663.x. Clin Exp Pharmacol Physiol. 2012. PMID: 22211842 Review.
-
Transforming growth factor-beta and Smad signalling in kidney diseases.Nephrology (Carlton). 2005 Feb;10(1):48-56. doi: 10.1111/j.1440-1797.2005.00334.x. Nephrology (Carlton). 2005. PMID: 15705182 Review.
Cited by
-
Roles of SIRT6 in kidney disease: a novel therapeutic target.Cell Mol Life Sci. 2021 Dec 24;79(1):53. doi: 10.1007/s00018-021-04061-9. Cell Mol Life Sci. 2021. PMID: 34950960 Free PMC article.
-
Ursolic acid inhibits epithelial-mesenchymal transition in vitro and in vivo.Pharm Biol. 2019 Dec;57(1):169-175. doi: 10.1080/13880209.2019.1577464. Pharm Biol. 2019. PMID: 30905239 Free PMC article.
-
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.Am J Nephrol. 2011;34(2):115-25. doi: 10.1159/000329327. Epub 2011 Jun 29. Am J Nephrol. 2011. PMID: 21720156 Free PMC article.
-
Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs.Mol Ther. 2013 Feb;21(2):388-98. doi: 10.1038/mt.2012.251. Epub 2012 Dec 4. Mol Ther. 2013. PMID: 23207693 Free PMC article.
-
Smad3 Signatures in Renal Inflammation and Fibrosis.Int J Biol Sci. 2022 Mar 28;18(7):2795-2806. doi: 10.7150/ijbs.71595. eCollection 2022. Int J Biol Sci. 2022. PMID: 35541902 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous